Press release
Ovarian Cancer Pipeline 2024 | Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co
Request a sample and discover the recent advances in Ovarian Cancer @ Ovarian Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Ovarian Cancer Pipeline Report
* August 2024:- AGO Research GmbH- This is a phase III, randomized, partially blinded, multicenter trial to evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared to placebo plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1st or 2nd relapse within 6 months after platinum based chemotherapy or 3rd relapse.
* August 2024:- Suzhou Suncadia Biopharmaceuticals Co., Ltd.- A Randomized, Open-Label, Controlled, Phase III Study of SHR-A1921 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer. This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of SHR-A1921 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.
* DelveInsight's Ovarian Cancer pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Ovarian Cancer treatment.
* The leading Ovarian Cancer Companies working in the market include Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics and others.
* Promising Ovarian Cancer Therapies in the various stages of development include SAR245409, Karenitecin, Topotecan, OTL38, Magrolimab, Avelumab, and others.
Learn more about Ovarian Cancer in clinical trials @ Ovarian Cancer Drugs [https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Ovarian Cancer Overview
Ovarian cancer is the leading cause of death in women diagnosed with gynecological cancers. It is also the fifth most frequent cause of death in women, in general. Most of the cases are diagnosed at an advanced stage, which leads to poor outcomes of this disease. Ovarian cancer can be further classified into two subtypes- Type I or Type II tumors, the latter being a more fatal variant, thought to be caused by continuous ovarian cycles leading to inflammation and endometriosis. Type I tumor includes low-grade serous, endometrioid, clear-cell, and mucinous carcinomas, with the rare subtypes being seromucinous and Brenner tumors. Type I tumors mostly arise from atypical proliferative (borderline) tumors.
Ovarian Cancer Emerging Drugs Profile
* Atezolizumab: Genentech
* Tisotumab Vedotin: Genmab
* SON-1010: Sonnet Biotherapeutics
* DS-6000a: Daiichi Sankyo Company
Discover more about Ovarian Cancer in development @ Ovarian Cancer Clinical Trials [https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Ovarian Cancer Therapeutics Assessment
There are approx. 180+ Ovarian Cancer companies which are developing the Ovarian Cancer therapies. The Ovarian Cancer companies which have their Ovarian Cancer drug candidates in the most advanced stage, i.e. phase III include, Genentech.
DelveInsight's Ovarian Cancer pipeline report covers around 200+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Ovarian Cancer Companies
Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics and others.
To know more about Ovarian Cancer, visit @ Ovarian Cancer Segmentation [https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Ovarian Cancer Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
For further information on the Ovarian Cancer Pipeline Therapeutics, reach out @ Ovarian Cancer Products Development [https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Ovarian Cancer Pipeline Report
* Coverage- Global
* Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Ovarian Cancer Companies- Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics and others.
* Ovarian Cancer Therapies- SAR245409, Karenitecin, Topotecan, OTL38, Magrolimab, Avelumab, and others.
Table of Content
* Introduction
* Executive Summary
* Ovarian Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Ovarian Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Atezolizumab: Genentech
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Tisotumab Vedotin: Genmab
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* DS-6000a: Daiichi Sankyo Company
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Product Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Ovarian Cancer Key Companies
* Ovarian Cancer Key Products
* Ovarian Cancer- Unmet Needs
* Ovarian Cancer- Market Drivers and Barriers
* Ovarian Cancer- Future Perspectives and Conclusion
* Ovarian Cancer Analyst Views
* Ovarian Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ovarian-cancer-pipeline-2024-allarity-therapeutics-ose-immunotherapeutic-cristal-therapeutics-bristolmyers-squibb-ono-pharmaceuticals-merck-co]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ovarian Cancer Pipeline 2024 | Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co here
News-ID: 3620113 • Views: …
More Releases from ABNewswire
Jesus Empire Launches 4G/5G Mobile Proxies to Empower Safe, U.S.-Sourced Social …
Real rotating 4G/5G LTE IPs (U.S. only) for safer multi-account management, geo-targeting, and automated engagement
Jesus Empire today announced the launch of Jesus Empire 4G/5G Mobile Proxies [https://jesusempire.com/jesus-empire-5g-mobile-proxies/], a next-generation proxy service providing real rotating U.S.-sourced 4G and 5G LTE IP addresses for creators, marketers, and automation agencies. By delivering genuine mobile IPs from U.S. carriers, Jesus Empire's proxies help clients scale social media campaigns with enhanced account safety, reduced ban…
Could the Next Breakthrough in Antibiotic Resistance Come From Viruses That Kill …
Antibiotic resistance has become one of medicine's most urgent challenges. The CDC estimates that resistant infections cause ~35,000 deaths each year in the U.S. and more than 1 million globally - a number projected to rise sharply over the next 25 years. Traditional drug development is struggling to keep pace, forcing healthcare systems to look beyond antibiotics altogether.
That search has reignited interest in a century-old idea that suddenly looks like…
Dermis Advanced Skin Care Introduces Cutting-Edge HydraFacial Technology to Otta …
Dermis Advanced Skin Care introduces cutting-edge HydraFacial technology to Ottawa's medical skin care clinic landscape. The non-invasive treatment delivers deep cleansing, exfoliation, and hydration for instantly radiant skin. Suitable for all skin types, HydraFacial reflects Dermis' commitment to innovation and excellence in advanced aesthetic care.
Ottawa, ON - October 27, 2025 - The growing demand for non-invasive facial rejuvenation continues to shape Ottawa's medical aesthetics scene, as Dermis Advanced Skin Care,…
Veltry Law, PC Gets Traffic Citation Points Dismissed and Massively Reduces Fine …
Islip, NY - Oct 27, 2025 - Veltry Law, PC, 309 Main St #1, Islip, NY 11751 [https://wwfvlaw.com/] (631) 234-5678, a respected Long Island, New York law firm, is proud to announce they are continuing the practice of reducing fines and erasing suspended license citations for traffic ticket offenses and aggravated unlicensed operation (AUO) in Suffolk and Nassau counties of Long Island, New York at their new location. 700+ 5-Star…
More Releases for Ovarian
Ovarian Cancer Diagnostics Market Size: 2033 Statistics
The Ovarian Cancer Diagnostics market is expected to grow from an estimated USD 4814.5 million in 2024 to USD 7795.1 million in 2033, at a CAGR of 5.50%.
The ovarian cancer diagnostics market plays a critical role in the early detection and management of ovarian cancer, one of the most common and lethal gynecological cancers worldwide. Ovarian cancer is often diagnosed at an advanced stage due to the lack of noticeable…
Ovarian Cancer Market Size, Future Trends
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Ovarian Cancer Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in…
Polycystic Ovarian Syndrome Treatment Market Report
The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth.
Browse…
How deadly is Ovarian Cancer?
Ovarian Drugs and Treatment Market describes its growth, size, share, Forecast and trends to 2025
Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body.
The global Ovarian Cancer Treatment Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025,…
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).…
Ovarian Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Ovarian Cancer - Heat Map and Analysis to its growing collection of premium market research reports.
Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in…
